Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 2004

View Archived Issues

Rheumatoid arthritis therapy modifies autoimmune response

Novel ocular hypotensive agent BVT-28949 effective in monkeys

Effective use of immediate-release and modified-release indiplon to treat insomnia

Potassium channel modulation blocks insulin release

Data support improved profile of cisapride analogue ATI-7505

Discovery of novel diamantane derivatives with antitumor activity and low toxicity

Evidence supports a better safety profile of viramidine in hepatitis C patients

Reduced esophageal motility found with baclofen in healthy volunteers

Phase III trial of Xolair begins in pediatric allergic asthma patients

FDA grants priority review to fixed dose combination of Viread and Emtriva

Ark to provide EG-005 on compassionate-use basis for patients ending phase II lipodystrophy trial

Largest-ever trial begins to evaluate efficacy and safety of IGIV for CIDP

Agenix updates ThromboView program

Aventis receives priority review designation for the expanded use of Taxotere

Aventis ends agreement with DeveloGen for DiaPep277

Pozen and GSK move new migraine treatment into phase III

Chemokine Therapeutics submits IND for CTCE-0214

Juvaris receives phase I SBIR grant for development of P. aeruginosa vaccine

Phase III trial begins with tifacogin as treatment for severe community-acquired pneumonia

Patient enrollment commences in phase I/II trial of E2F decoy

Elan and Biogen Idec to file for approval of Antegren for Crohn's disease in Europe

Elan and Vernalis finalize agreement regarding Frova

Idenix reports phase I/II clinical trial data for NM-283 as treatment of hepatitis C

Data on anidulafungin activity, pharmacokinetics presented

Olpadronate increases bone strength in mice

Cinacalcet controls parathyroid hormone in kidney disease patients

More erythromycin antibiotics in early development at Enanta

Fournier presents new hypoglycemic and hypolipidemic agents

Novel CRF antagonists prepared and tested at BMS

Bayer describes novel guanylate cyclase activators with utility in cognition disorders

Dual PPARalpha/PPARgamma agonists and their use claimed by Merck KGaA

Roche scientists identify new PPARalpha/PPARgamma agonists

New glucokinase activators covered by Roche patent

GSK researchers design dopamine/5-HT receptor ligands for schizophrenia and drug abuse